natgillin/translations-raw huggingface dataset:
for use in a method for treating muscle cramps, musculoskeletal irritability, or for improving muscle recovery in a subject in need thereof, and wherein said composition is an oral formulation that is a liquid, beverage, gel, solid, semi-solid, chewing gum, or spray, preferably wherein said TRP channel activators are independently selected from capsicum; cinnamon volatile oil; and 
(c) gingerola, za upotrebu u postupku liječenja mišićnih grčeva, mišićno-skeletne nadraženosti, ili za poboljšanje oporavka mišića kod subjekta kojem je to potrebno, pri čemu je navedeni pripravak oralna formulacija koja je tekućina, napitak, gel, čvrsta tvar, polukruta tvar, guma za žvakanje, ili sprej, pri čemu navedeni pripravak sadrži aktivator TRPV1 kanala pri čemu je navedeni aktivator TRPVI kanala kapsaicin ili drugi kapsaicinoid poželjno pri čemu su navedeni aktivatori TRP kanala neovisno odabrani od
A compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein m and n are independently 0, 1, or 2; 
Spoj formule (I) [image] ili njegova farmaceutski prihvatljiva sol, gdje m i n su nezavisno 0,1 ili 2;
a plurality of positioning ramps (11-1, 12-1, 13-1, 14-1...) mounted in correspondence of a respective rotating blade, 
- mnoštvo rampi za pozicioniranje (11-1, 12-1, 13-1, 14-1...) montiranih da se podudaraju s odgovarajućom Totirajućom oštricom,
In addition, the pharmaceutical composition is provided as an aerosol or spray package. 
Aerosolno ili sprejno pakiranje, naznačeno time što sadrži farmaceutski pripravak u skladu s patentnim zahtjevom
preparing a solution or suspension of mesoporphyrin IX dihydrochloride or a salt thereof by: 
pripravi otopine ili suspenzije Mezoporfirin IX-dihidroklorida, ili njegove soli:
A method of screening for a peptide which 1, 2, or several amino acids are substituted, wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: SEQ ID NO: 19, 22, 30, 34, 344, 358, 41. 
Peptid od manje od 15 aminokiselina koja može inducirati citotoksične T-stanice, gdje navedeni peptid ima aminokiselinski slijed kojeg se bira iz skupine koju čine SEQ ID NO: 30, 19, 22, 34, te 358, u kojem su 1 ili 2 aminokiseline zamijenjene, izbačene ili dodane, naznačen time što navedeni peptid inducira citotoksične 'T- limfocite specifične za stanicu koja eksprimira CDH3.
The composition of claim 12, wherein the specific turbidity of the composition is between 0.3 cm2/g and 0.6 cm2/g. 
Sastav prema patentnom zahtjevu 12, naznačen time, da je specifična zamućenost sastava između 0,3 cm?/g i 0,6 cm'"/g.
A dosage form according to claim 1, which comprises at least one active ingredient at least partially in controlled release form. 
Oblik davanja lijeka prema jednom od patentnih zahtjeva 1 do 12, naznačen time, da sadrži barem jednu djelatnu tvar barem djelomično u obliku s produženim oslobađanjem.
The shell (or the outer shell) can be box-shaped. It can also comprise rounded edges, wherein preferably the longitudinal edges between the front wall and both lateral walls are rounded. 
Omot za pakiranje u skladu s bilo kojim od patentnih zahtjeva 1 do 21, naznačen time što vanjska ljuska ima zaobljene bridove, pri čemu je poželjno da se zaobljeni uzdužni bridovi nalaze između prednje stijenke i obiju bočnih stijenki.
It is advantageous if the diaper accessory has a predefined set of filters for improving the differentiation between critical and noncritical movement patterns and/or excretion patterns. 
Postupak prema jednom od zahtjeva 1 do 4, kod kojeg modul pelene (2) ima unaprijed definirani skup filtera za poboljšanje diferencijacije između definiranih i nedefiniranih uzoraka pokreta i/ili uzoraka izlučevina.
A combination according to claim 8 wherein the active compound (c) is selected from the group consisting of (a) B2-agonists and (b) cortiocosteroids. 
Kombinacija sukladno patentnom zahtjevu 9, naznačena time, da je djelatni spoj (c) odabran iz skupine koja se sastoji od (a) inhibitora PDE IV i (b) kortikosteroida.
The method according to one or more of claims 10 to 15, wherein the ink or coating composition is selected from the group of inks comprising screen-printing inks, gravure inks and flexographic inks. 
Postupak sukladno jednom od patentnih zahtjeva 7 do 12, naznačen time, da je tinta ili smjesa za premazivanje odabrana iz skupine koju čine tinte za tiskanje zaslonom, tinte za graviranje i fleksografske tinte.
or a pharmaceutically acceptable salt thereof. 
<Tz. ili njegova farmaceutski prihvatljiva sol.
A counter as claimed in claim 2 wherein said coupling mechanism comprises first and second engagement means, said first engagement means being movable radially outwardly and radially inwardly relative to said axis. A counter comprising: 
Brojač kao što je navedeno u zahtjevu 2 naznačeno time da navedeni mehanizam sparivanja (700) sadrži prvo i drugo sredstvo uključenja (704, 705, 1516), navedeno prvo sredstvo uključenja bivajući pomično radijalno prema van i radijalno prema unutra u odnosu na spomenutu os.
wherein "5-membered heterocyclic ring" denotes a 5-membered carbocyclic ring wherein 1, 2, or 3 ring carbons not shared by Rings A and B are independently replaced with -O-, -S-, -S(O)-, or -S(O)2-, and wherein Ring A is optionally substituted with 1 to 4 substituents selected from: halogen, 
Prsten A 1B, te gdje "5-člani heterociklički prsten" označava 5-člani karbociklički prsten u kojem 1, 2 ili 3 ugljika prstena koje ne dijele Prsten A i B su nezavisno zamijenjeni sa -O-, -S-, ili S(O),, te gdje je Prsten A po izboru supstituiran sa 1 do 4 supstituenda izabrana iz skupine koju čine: halogen, hidroksi, tioksi, cijano, nitro,
In this case, the starting material of the purification process of the invention is serum-free cell culture supernatant that mainly contains host cell proteins as impurities. 
Na taj način početni materijal koji se koristi u procesu pročišćavanja iz ovoga izuma ne sadrži supernatant u kojemu ima proteina iz seruma premda taj supernatant sadrži proteine iz kultiviranih stanica.
The method, according to the present invention, comprises or consists of the following steps 1 to 4: 
Postupak, u skladu s ovim izumom, sadrži ili se sastoji od sljedećih koraka 1 do 4:
The invert arm assembly of claim 2 wherein said first and second nuts are each operably associated with a separate one of the ball spline nuts so that the ball spline nuts slidably reciprocate along said ball spline shaft as the first and second nuts reciprocate along said ball screw in response to rotation of the ball screw. 
Sklop invertirajuće ruke iz zahtjeva 2 naznačen time da su spomenute prva i druga matica svaka operativno povezana s jednom od kuglasto-klinastih matica tako da se kuglasto-klinaste matice mogu klizno pomicati uzduž spomenute kuglasto-klinaste osovine kako se pomiču prva i druga matica uzduž spomenutog kuglastog vijka zbog okretanja kuglastog vijka.
wherein the aspirin and alkaline substances are contained in a single layer. 
od 1400 do 2000 mg alkalnih tvari, naznačena time da su aspirin i alkalne tvari sadržane u jednom sloju.
The filter system as per Claim 4, characterised in that the volume of the filtered water space (9) is at least as big as the volume of the filtered water tank (12). 
je volumen prostora za filtriranu vodu (9) najmanje toliko velik koliko i volumen spremnika za filtriranu vodu (12),
The use according to claim 8, wherein the pharmaceutical co-formulation is for use in treating type I diabetes, type II diabetes, or a metabolic syndrome. 
Mimetik kalcitonina za primjenu sukladno patentnom zahtjevu 2, pri čemu je mimetik kalcitonina za primjenu u liječenju dijabetesa tipa I, dijabetesa tipa II, ili metaboličkog sindroma.
R1' is linear or branched C1-C4 alkyl or C3-C4 cycloalkyl, each of said alkyl or cycloakyl groups being optionally substituted by one or more group(s) selected from halo or esters; 
’ je linearni ili razgranati C1-C4 alkil ili C3-C4 cikloalkil, svaki od navedenih alkil ili cikloakil groupa je po izboru supstituirana jednom ili više groupa izabranih iz halo ili esteri;
An antagonist of M3 muscarinic receptors for use according to claim 20 wherein the patient is suffering from a pre-existing heart condition or condition that would be aggravated by tachycardia A B2 agonist as defined in any one of claims 1 and 3 to 7, for simultaneous, concurrent, separate or sequential use in combination with an antagonist of M3 muscarinic receptors as defined in claim 1 or 2 for the treatment of a respiratory disease as defined in claim 11 or 12. 
Antagonist M3 muskarinskih receptora, za uporabu u skladu sa zahtjevom 16, naznačen time, da pacijent pati od postojećeg stanje srca ili stanja koje će biti pogoršano tahikardijom B2 agonist kako je definirano u patentnom zahtjevu 1 ili 3, naznačen time, da je namijenjen za istovremenu, paralelnu, odvojenu ili sekvencijalnu uporabu u kombinaciji s antagonistom M3 muskarinskih receptora kako je definirano u patentnom zahtjevu 1 1li 2 za liječenje dišnih bolesti kao što je definirano u zahtjevu 7 ili 8.
Thus, in a first aspect the present invention provides a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster 3 of BCMA(CQLRCSSNTPPLTCQRYC) (SEQ ID NO:1016); and 
HR P20191697 T1 PATENTNI ZAHTJEVI Vezujuća molekula koja je barem bispecifična koja sadrži prvu i drugu vezujuću domenu, naznačena time što (a) prva vezujuća domena sposobna _ je za vezanje na epitop klastera 3 od BCMA (CQLRCSSNTPPLTCQRYC); i
In addition Gemzar® may be used in the treatment of HCV as well as a modulator of immune function (see U.S. Pat. No 6,555,518). 
Uz to, Gemzar" se može upotrijebiti i u liječenju HCV, te kao modulator funkcije imunosnog sustava (vidjeti US patent br 6,555,518).
immediate cooling of the solution obtained in step a) to a temperature lower than 55°C, preferably to a temperature ranging from 45°C to 55°C, followed by further cooling until incipient crystallisation occurs; cooling to 20-25°C of the mass obtained in step b) in the presence of stirring at the rate of 60-120 rpm, followed by further stirring of the mass at 20-25°C for a time ranging from 2 to 12 hours; 
C) hlađenje do 20-25"C mase dobivene u koraku b) uz miješanje pri brzini od 60-120 rpm, zatim daljnje miješanje mase pri 20-25*C u rasponu vremena od 2 do 12 sati; d) polagano dodavanje u suspenziju dobivenu u c) otapala koje je odabrano iz skupine koju čine aceton, etanol ili metanol, preferirano aceton, zatim hlađenje dobivene suspenzije pri temperaturi u rasponu od 3"C do TC;
provided that R1 is not methyl when R3 is morpholinyl or furyl; wherein R6 and R7 are independently selected from the group consisting of hydrogen, alkyl of 1-6 carbon atoms, or cycloalkyl of 3-8 carbon atoms; or R6 and R7 when taken together with the nitrogen to which they are attached form a heterocycle; 
pod uvjetom da R1 nije metil kada je R3 morfolinil ili furil; gdje su R6 i R7 nezavisno izabrani iz grupe koja se sastoji od vodika, alkila sa 1-6 ugljikovih atoma, ili cikloalkila sa 3-8 ugljikovih atoma; ili
Even more preferably, the colour of the thermochromic ink is, below the predetermined temperature, as similar as possible to that of the conventional ink with which the marking has been printed. BRIEF DESCRIPTION OF THE DRAWINGS 
Postupak prema bilo kojem od zahtjeva 6, 7 ili 8, naznačen time, da je obojenje termokromne tiskarske boje ispod spomenute predodređene temperature, što je više moguće slično onom obojenju od konvencionalne tiskarske boje kojom je otisnuta oznaka (12').
The glass fiber composition according to claim 1, characterized by the range of the weight percentage ratio C2 = CaO/MgO being greater than 1 and less than 1.3. 
Sastav staklenog vlakna prema zahtjevu 1, naznačen time, da raspon omjera masenog postotka C2 = Cao / MgO iznosi više od 1 i manje od 1,3.
is selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl; 
Rio je izabran od vodika, alkila, cikloalkila, arila, heteroarila i heterociklila;
R2c represents a hydrogen atom, a halogen atom, a hydroxy group, C1-6 alkyl which may be substituted by a fluorine atom or C1-6 alkoxy which may be substituted by a fluorine atom, or a pharmaceutically acceptable salt thereof. 
R*" predstavlja atom vodika, atom halogena, hidroksi skupinu, C;.4 alkil koji može biti supstituiran atomom fluora ili Cig alkoksi koji može biti supstituiran atomom fluora, ili prolijek, ili farmaceutski prihvatljiva sol.
The formulation of any one of claims 1-2, wherein the mixture of PFC's comprises perfluoropropane, perfluorobutane, perfluoropentane, perfluorohexane, perfluorodecalin, perfluorodimethyl-cyclohexane, perfluoroperhydrophenanthrene, pentafluoropropane, perfluorotripropylamine, C6-C9 perfluoroalkanes, perfluoroperhydrofluoranthrene, perfluorodecalin, perfluoroperhydro-phenanthrene, bis(perfluor-hexyl)-1,2-ethene, perfluoro-1,3-dimethylcyclohexane, perfluoro-methyldecalin, perfluoroisopropyldecalin, a mixture of perfluorodixylylmethane and perfluorodixylylethane, and/or a mixture of perfluoroperhydrophenanthrene and perfluoro n-butyl decalin. 
Formulacija prema jednom od zahtjeva 1-2, naznačena time što smjesa PFC sadrži perfluoropropan, perfluorobutan, perfluoropentan, perfluoroheksan, perfluordekalin, perfluordimetilcikloheksan, perfluorperhidrofenantren, pentafluorpropan, perfluortripropilamin, C6-C9-perfluoralkane, perfluoroperhidrofluorantren, perfluordekalin, perfluorperhidrofenantren, bis(perfluorheksil)-1,2-eten, perfluor-1,3-dimetilcikloheksan, perfluormetildekalin, perfluorizopropildekalin, smjesu perfluordiksililmetana i perfluordiksilietana i/ili smjesu perfluorperhidrofenantrena i perfluor-n-butildekalina.
it has a higher degree of sialylation than is reached in DSM ACC2606 (NM-F9) or DSM ACC2605 (NM-D4) cells; wherein the DSM ACC2606 (NM-F9) and DSM ACC2605 (NM-D4) cells only reach about 50 to 60% of the sialylation degree that is obtained with the immortalized human blood cell. 
- ima veći stupanj sijaliliranja od onog postignutog kod stanica DSM ACC2606 (NM-F9) ii DSM ACC2605 (NM-D4); gdje stanice DSM ACC2606 (NM-F9) 1 DSM ACC2605 (NM-D4) postižu samo otprilike 50 do 60% od stupnja sijaliliranja postignutog s imortaliziranom stanicom iz ljudske krvi.
A nucleic acid, exclusively encoding a peptide according to any one of Claims 1 to 6. 
Nukleinska kiselina koja se sastoji od niza koji kodira peptid prema Zahtjevu 1. ili 2.
The method according to claim 1, further comprising the step of connecting at least two prefabricated modules to each other in the direction of the height of the modules. 
Postupak sukladno bilo kojem od prethodnih zahtjeva, nadalje sadrži korak spajanja barem dva prethodno proizvedena modula u smjeru duljine modula.
The pharmaceutical composition of claim 9, wherein the Mtb72f fusion protein is a polypeptide consisting of residues 1 and 4-725 of SEQ ID NO:4 optionally with a His tag inserted following the initial Met residue. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 9, naznačen time što je fuzijski protein Mtb72f polpeptid koji se sastoji od ostataka 1 14-725 iz SEQ ID NO<4, izborno s ubačenim biljegom His iza početnog ostatka Met.
The process of claim 22, wherein testing was performed at one of the following stages: infection, growth stages, harvest, processing, splitting, surface protein extraction, and vaccine formulation. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se testiranje provodi kod jednog od sljedećih stupnjeva: virusna infekcija, stadiji rasta, prikupljanje virusa, procesuiranje virusa, razdvajanje, ekstrakcija membranskih proteina, formuliranje cjepiva, pakiranje cjepiva.
the compound of formula (XXX) is subjected to an alkylation reaction in the presence of a halide Rc"X, Rc" being as defined in Claim 1 and X being a halogen, and in the presence of a base. 
spoj s formulom (XXX) se podvrgava reakciji alkilacije u prisutnosti halogenida Rc"X, te je Rc" kako je definirano u zahtjevu 1 i X je halogen, te u prisutnosti baze.
and pharmaceutically acceptable salts, esters, and/or stereoisomers thereof. 
N ili njegovih farmaceutski prihvatljivih soli, solvata, estera, i/ili stereoizomera.
The liquefied gas treatment system according to claim 1, wherein the third stream liquefied in the heat exchanger is decompressed by decompressing means. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što se treću struju, ukapljenu u izmjenjivaču topline (21), dekomprimira elementom za dekomprimiranje (22).
The method according to claim 1 wherein the cancer is carcinoma of the bladder, breast, colon, kidney, epidermis, liver, lung, oesophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, nose, head and neck, prostate, or skin; a hematopoietic tumour of lymphoid lineage; a hematopoietic tumour of myeloid lineage; thyroid follicular cancer; a tumour of mesenchymal origin; a tumour of the central or peripheral nervous system; melanoma; seminoma; teratocarcinoma; osteosarcoma; xeroderma pigmentosum; keratoctanthoma; thyroid follicular cancer; or Kaposi's sarcoma. 
Spoj za uporabu prema zahtjevu 6, naznačen time, da rak je sarkom, leukemija, gliom, porodični melanom ili melanom. Spoj za uporabu prema zahtjevu 6, naznačen time, da rak je karcinom mjehura, dojke, crijeva, bubrega, epiderme, jetre, pluća, ezofagusa, žučnog mjehura, jajnika, gušterače, želuca, cerviksa, tiroidne žlijezde, nosa, glave i vrata, prostate ili kože; hematopoietički tumor limfoidnog podrijetla; hematopoietički tumor mijeloidnog podrijetla; tiroidni folikularni rak; tumor mezenhimalnog postanka; tumor centralnog ili
wherein the presence of said 10 to 200 PPM polysorbate 20 or Triton® X-100 in said aqueous solution reduces fouling of said ultrafiltration membrane by at least 50% as compared to not adding said 10 to 200 PPM polysorbate 20 or Triton® X-100 in said aqueous solution, and wherein said step of filtering said aqueous solution is by normal flow filtration. The method of claim 1, wherein said ultrafiltration membrane is a parvovirus retentive membrane. 
filtriranja spomenute vodene otopine koja sadrži 10 do 200 ppm polisorbata 20 ili Tritona® X-100, kroz spomenute ultrafiltracijske membrane, pri čemu prisutnost spomenutih 10 do 200 ppm polisorbata 20 ili Tritona® X-100 u spomenutoj vodenoj otopini, smanjuje začepljenje spomenute ultrafiltracijske membrane za najmanje 50% u usporedbi s nedodavanjem spomenutih 10 do 200 ppm polisorbata 20 ili Tritona® X-100 u spomenutu vodenu otopinu, te time, da se spomenuti korak filtriranja spomenute vodene otopine odvija putem normalne protočne filtracije.
The method according to claim 1, wherein the pathological condition is selected from the group consisting of arthritis, inflammatory bowel diseases, eczema, and neurodermatitis. The method according to claim 1, where the pathological condition is vascularization triggered by breast cancer or by prostate cancer. 
Spoj namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je namijenjen sprječavanju ili inhibiranju vaskulariziranja u upalnom stanju, osobito kada se upalno stanje bira iz skupine koju čine artritis, upalne bolesti crijeva, egzem, te neurodermatitis.
Method of manufacturing the extended release tablet formulation according to one of the claims 1 to 17, via a dry granulation process comprising the steps of 
Postupak priprave formulacije tablete produljenog oslobađanja u skladu s jednim od prethodnih zahtjeva 1 do 10, pomoću postupka suhog granuliranja, naznačen time, da sadrži slijedeće korake
/ Clinical experiences Clinical experiences with only a small number of patients indicate a potential therapeutical benefit of using the tolperisone:dextromethorphan 5:1 fixed-dose combination for different neurological indications. 
Klinički pokusi sa samo malim brojem pacijenata pokazuju moguću terapeutsku korist od upotrebe fiksne doze kombinacije tolperisona i dekstrometorfana od 5:1 za različite neurološke indikacije.
Pertuzumab for use according to claim 6 wherein the chemotherapeutic agent is an antimetabolite chemotherapeutic agent. 
Pertuzumab za uporabu prema zahtjevu 6, naznačen time, da kemoterapeutsko sredstvo je antimetaboličko kemoterapeutsko sredstvo.
output unit configured to generate a bitstream including the mode prediction flag and the mode index, wherein, the candidate list determiner determines the candidate intra prediction modes to include a planar mode, when the intra prediction modes of the left block and the upper block are equal to each other and the intra mode of the left block is the DC mode. 
- < provođenje unutrašnjeg predviđanja trenutnog bloka uz korištenje načina predviđanja, koji je određen s indeksom načina, između kandidata načina unutrašnjeg predviđanja koji su uključeni u popis kandidata, naznačen time da popis kandidata načina unutrašnjeg predviđanja sadrži ravninski način, kada su načini unutrašnjeg predviđanja lijevog bloka 1 gornjega bloka međusobno jednaki i unutrašnji način lijevog bloka je DC način.
For example, the introduction of one or more polyethylene glycol (PEG) groups onto the linker enhances the hydrophilicity and water solubility of the rapamycin carbohydrate derivative, increases both molecular weight and molecular size and, depending on the nature of the unPEGylated linker, may increase the in vivo retention time. 
Na primjer, uvođenje jedne ili više polietilen-glikolnih (PEG) grupa u veznik povećava hidrofilnost i topljivost ugljikohidratnog derivata rapamicina u vodi, povećava molekulsku masu i veličinu i, ovisno o prirodi ne-PEG-iliranog veznika, može povećati retencijsko vrijeme in vivo.
The oligonucleotide-based compound according to any one of claims 8 to 14, which is to be administered in conjunction with one or more vaccines, antigens, antibodies, cytotoxic agents, allergens, antibiotics, TLR agonist, TLR antagonist, siRNA molecules, miRNA molecules, antisense oligonucleotides, aptamers, proteins, peptides, gene therapy vectors, DNA vaccines, adjuvants, co-stimulatory molecules or combinations thereof. 
Spoj na bazi oligonukleotida prema bilo kojem od zahtjev 9 do 15, koji se primjenjuje u kombinaciji s jednim ili više cjepiva, antigena, protutijela, citotoksičnih sredstava, alergena, antibiotika, TLR agonista, TLR antagonista, siRNA molekula, rniRNA molekula, antisense nukleotida, aptamera, proteina, peptida, vektora genske terapije, DNA cjepiva, adjuvansa, antagonista proteinske aktivnosti, kinaznih inhibitora, kemoterapeutika, ciljanih terapijskih sredstava, ko-stimulatornih molekula ili njihovih kombinacija.
The radioligand was 0.025 nM [35S] GTP-Y-S and non specific binding determined in the presence of 10 µM non-radioactive GTP-Y-S. 
Radioligand je bio 0,025 nM [*S]-GTP-y-S, a HR P20080431 T3 nespecifično vezanje određeno je u prisutnosti 10 uM neradicaktivnog GTP-y-S.
correlating the results of the determinations, thereby predicting a response to treatment for alcoholism in a subject. 
SS genotipom; koreliranje rezultata određivanja, stoga predviđanje odgovora na liječenje alkoholizma u ispitanika.
Indeed there is evidence that lithium, an uncompetitive inhibitor of GSK3p, enhances neuritogenesis in some models and also increases neuronal survival, through the induction of survival factors such as Bcl-2 and the inhibition of the expression of proapoptotic factors such as P53 and Bax. 
I doista, postoji dokaz da litij, nekompetitivni inhibitor GSK3R, pojačava neuritogenezu u nekim modelima, a također povećava i preživljenje neurona, indukcijom čimbenika preživljavanja, poput Bcl-2, te inhibicijom eksprezije proapoptotskih čimbenika, poput P53 i Bax.
In view of the presented results it can be concluded that the present invention achieves all previously defined objects and avoids the drawbacks of the prior art solutions. 
Iz prikaza postignutih rezultata vidi se, da izum dostiže sve postavljene ciljeve, te uklanja nedostatke dosadašnjeg stanja tehnike.
The salt according to claim 1, which salt is the hydrogen fumarate salt of the compound of formula [I]. 
Sol u skladu s patentnim zahtjevom 1, naznačena time, što je to sol vodikovog fumarata spoja formule [I].
Biological efficacy of compounds of the invention 
Datum objave europske prijave patenta: